2012 EDUCATIONAL BOOK - American Society of Clinical Oncology

LUNG CANCER IN BRAZIL
Author’s Disclosure of Potential Conflicts of Interest
Author
Gilberto Schwartsmann*
*No relevant relationships to disclose.
Employment or
Leadership
Positions
Consultant or
Advisory Role
1. Siegel R, Naishadham D, Jemal A. Cancer statistics, CA Cancer J Clin.
2012;62:10-29.
2. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of
cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-2917.
3. Instituto Nacional de Câncer and Ministério da Saúde. Estimativa 2012:
Incidência de câncer no Brasil. Rio de Janeiro: INCA. http://www.inca.gov.br.
Accessed January 2012.
4. Souza MC, Vasconcelos AGG, Cruz OG. Trends in lung cancer mortality
in Brazil from the 1980s into the early 21st century: age-period-cohort
analysis. Cad Saude Publica. 2012;28:21-30.
5. Santoro IL, Ramos RP, Franceschini J, et al. Non-small cell lung cancer
in never smokers: A clinical entity to be identified. Clinics (Sao Paulo).
2011;66:1873-1877.
6. Monteiro CA, Cavalcante TM, Moura EC, et al. Population-based evidence
of a strong decline in the prevalence of smokers in Brazil (1989-2003).
Bull World Health Organ. 2007;85:527-534.
7. McLoud TC. Initial results of the National Lung Cancer Screening Trial.
Cancer Imaging. 2011;11:S85.
8. Novaes FT, Cataneo DC, Ruiz Junior RL, et al. Lung cancer: Histology,
staging, treatment and survival. J Bras Pneumol. 2008;34:595-600.
9. Westphal FL, Lima LC, Andrade EO, et al. Characteristics of patients
with lung cancer in the city of Manaus. Brazil J Bras Pneumol. 2009;35:157-
163.
10. Melo, ACD, Inada HKP, Barros M, et al. Non-small cell lung cancer
(NSCLC) genotyping in a Brazilian cohort. Poster Session P2.123 presented
at 14th World Conference on Lung Cancer; 2011; Amsterdam, NL.
11. Janssen-Heijnen ML, Coebergh JW. Trends in incidence and prognosis
of the histological subtypes of lung cancer in North America, Australia, New
Zealand and Europe. Lung Cancer. 2001;31:123-137.
12. Ettinger DS, Akerley W, Bepler G, et al. Non-small cell lung cancer.
J Natl Compr Canc Netw. 2010;8:740-801.
13. Chatkin JM, Abreu CM, Fritscher CC, et al. Is there a gender difference
in non-small cell lung cancer survival? Gend Med. 2004;1:41-47.
14. Paik PK, Arcila ME, Fara M, et al. Clinical characteristics of patients
with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol. 2011;
29:2046-2051.
15. Wislez M, Lavolé A, Gounant V, et al. Bronchiolar-alveolar carcinoma:
From concept to innovative therapeutic strategies. Presse Med. 2011;40:389-
397.
16. Younes RN, Schutz FA, Gross JL. Preoperative and pathological
staging of NSCLC: Retrospective analysis of 291 cases. Rev Assoc Med Bras.
2010;56:237-241.
17. Hochhegger B, Marchiori E, Sedlaczek O, et al. MRI in lung cancer: A
pictorial essay. Br J Radiol. 2011;84:661-668.
18. Ren JH, He WS, Yan GL, et al. EGFR mutations in non-small-cell lung
cancer among smokers and non-smokers: A meta-analysis. Environ Mol
Mutagen. 2012;53:78-82.
Stock
Ownership Honoraria
REFERENCES
Research
Funding
Expert
Testimony
Other
Remuneration
19. Vilmar A, Sørensen JB. Excision repair cross-complementation group 1
(ERCC1) in platinum-based treatment of non-small cell lung cancer with
special emphasis on carboplatin: A review of current literature. Lung Cancer.
2009;64:131-139.
20. Gaughan EM, Costa DB. Genotype-driven therapies for non-small cell
lung cancer: Focus on EGFR, KRAS and ALK gene abnormalities. Ther Adv
Med Oncol. 2011;3:113-125.
21. Ryu JS, Shin ES, Nam HS, et al. Differential effect of polymorphisms of
CMPK1 and RRM1 on survival in advanced non-small cell lung cancer
patients treated with gemcitabine or taxane/cisplatinum. J Thorac Oncol.
2011;6:1320-1329.
22. Younes RN, Deutsch F, Badra C, et al. Nonsmall cell lung cancer:
Evaluation of 737 consecutive patients in a single institution. Rev Hosp Clin
Fac Med Sao Paulo. 2004;59:119-127.
23. NSCLC Meta-analyses Collaborative Group, Arriagada R, Auperin A,
et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in
operable non-small-cell lung cancer: Two meta-analyses of individual patient
data. Lancet. 2010;375:1267-1277.
24. Martins RG, Dienstmann R, de Biasi P, et al. Phase II trial of
neoadjuvant chemotherapy using alternating doublets in non-small-cell lung
cancer. Clin Lung Cancer. 2007;8:257-263.
25. Anelli A, Lima CA, Younes RN, et al. Chemotherapy versus best
supportive care in stage IV non-small cell lung cancer, non metastatic to the
brain. Rev Hosp Clin Fac Med Sao Paulo. 2001;56:53-58.
26. Naime FF, Younes RN, Kersten BG, et al. Metastatic non-small cell
lung cancer in Brazil: Treatment heterogeneity in routine clinical practice.
Clinics (Sao Paulo). 2007;62:397-404.
27. Botrel TE, Clark O, Clark L, et al. Efficacy of bevacizumab (Bev) plus
chemotherapy (CT) compared to CT alone in previously untreated locally
advanced or metastatic non-small cell lung cancer (NSCLC): systematic
review and meta-analysis Lung Cancer. 2011;74:89-97.
28. Azzoli CG, Temin S, Aliff T, et al. 2011 Focused Update of 2009
American Society of Clinical Oncology Clinical Practice Guideline Update on
Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. J Clin Oncol.
2011;29:3825-3831.
29. Planchard D, Le Péchoux C. Small cell lung cancer: New clinical
recommendations and current status of biomarker assessment. Eur J Cancer.
2011;47 Suppl 3:S272-S283.
30. Lima JP, dos Santos LV, Sasse EC, et al. Camptothecins compared with
etoposide in combination with platinum analog in extensive stage small cell
lung cancer: Systematic review with meta-analysis. J Thorac Oncol. 2010;5:
1986-1993.
31. Brazilian Institute of Geography and Statistics - Instituto Brasileiro de
Geografia e Estatística (IBGE), Brazil, 2011. www.ibge.gov.br. Accessed
January 2012.
431